KalVista Pharmaceuticals (KALV) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for sebetralstat, an oral plasma kallikrein inhibitor, for symptomatic treatment of acute attacks of hereditary angioedema in adults and adolescents aged 12 years and older. The European Commission final decision is expected by early October.
Sebetralstat is approved in the United States and United Kingdom under the brand name EKTERLY for the treatment of hereditary angioedema attacks in people 12 years of age and older.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.